Psychedelic Bulletin 207 highlights Lykos rebrand to Resilient Pharma, Norway ketamine reimbursement pushback, and AbbVie deal validation

Psychedelic Bulletin 207 connects corporate and policy moves shaping psychedelics and ketamine access. Lykos’ rebrand to Resilient Pharma is framed as a strategic repositioning while the company challenges Norway’s decision on ketamine reimbursement. The bulletin also covers an AbbVie-Gilgamesh deal, interpreting the partnership as external validation of momentum in the sector. The overall theme is how company branding, regulatory outcomes, and big pharma partnerships interact to influence market confidence and future commercialization.